People | February 23, 2022
Sumitomo Dainippon Pharma Oncology appoints Jatin J. Shah as Chief Medical Officer
Dr. Shah will lead strategic and operational clinical development of the company's diverse pipeline
Dr. Shah will lead strategic and operational clinical development of the company's diverse pipeline
The FDA's Orphan Drug Designation is granted to investigational therapies addressing rare medical diseases or conditions that affect fewer than 200,000 people
TP-3654 is currently being evaluated in a Phase 1/2, multicenter, dose-escalation, open-label trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with intermediate or high-risk primary or secondary myelofibrosis.
Subscribe To Our Newsletter & Stay Updated
